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Abstract
Background: Ischemic heart disease (IHD) is one of the most important causes of mortality and
morbidity in the Western world. There is a relationship between aging of the lens of the human
eye and cardiovascular disease. The present study was conducted to examine if the risk of ischemic
heart disease could be estimated by fluorophotometric assessment of lens aging.
Methods: A total of 421 subjects were included. Risk of IHD was estimated from non-ocular data
using the Precard ® software. Lens aging was quantified by lens fluorometry.
Results: The risk of IHD was strongly related to lens fluorophore accumulation (p = 0.001). The
relationship between IHD and lens aging was attributable to tobacco smoking and dysglycemia.
Conclusion: The risk of ischemic heart disease related to smoking and diabetes mellitus can be
estimated using the aging of the lens of the eye as a biomarker for generalized tissue-damage.
Background
Ischemic heart disease (IHD) is the most common cause
of death in the Western world [1]. Major risk factors are
diabetes mellitus, smoking, and dyslipidemia [2-4]. An
association between cataract and cardiovascular disease
has been demonstrated previously [5,6]. Cataract is an
opacification of lens of the human eye interfering with
visual function. Senile cataract is a common disease asso-
ciated with oxidative stress, [7,8] smoking, [9,6,3,10,11]
and diabetes mellitus [6,12].
The association between aging of the lens and ischemic
heart disease may well be a causative one. Both lens pro-
teins, plasma proteins, and the collagen of the vascular
walls are subject to denaturation by a spontaneous reac-
tion between aminogroups and reducing sugars, [13] gly-
cotoxins from tobacco smoke, [14] or lipid peroxidation
products [15]. The spontaneous reaction leads to forma-
tion of advanced glycation end products (AGEs).
Advanced glycation end products have been shown to
increase atherogenicity of LDL-particles [16] as well as
playing a role in stiffening of arterial vessel walls [17] both
of which are important features in the pathogenesis of
IHD. In the lens of the human eye, AGEs lead to accumu-
lation of yellow, fluorescent compounds [18,19] thus
causing the intrinsic fluorescence [20].
Targeting premorbid cardiovascular disease prevention in
individuals at high risk depends upon the availability of
biomarkers of long-term morbidity and mortality risk. At
present, detection of subjects at high risk for IHD is based
on risk assessment from a combination of informations
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from blood tests, lifestyle, and genetic predisposition
[21]. Substituting these with a single measurement or
biomarker would be advantageous. The search for a non-
invasive biomarker for cardiovascular disease is ongoing
[22-24]. Cataract is a marker of the risk of and/or presence
of cardiovascular disease, but the grading of cataract and
its subclinical precursors is generally subjective and crude.
We hypothesized that assessment of age-related changes
in the lens could be used as a biomarker for IHD. The
intrinsic fluorescence of the lens is an alternative objective
parameter of lens aging that can be measured fast, non-
invasively, and without pupil dilation. Another objective
measurement of lens ageing, Scheimpflug photography,
exists. However, it requires medical pupil dilation which
makes it a less attractive instrument in the present context.
In the present study we compared lens fluorometry with
an established method of prediction of ischemic heart dis-
ease risk in healthy individuals.
Methods
Study population
Subjects were enrolled from a prospective epidemiologic
study on the prevalence of ischemic heart disease (IHD)
and effect of non-pharmalogical intervention on IHD risk
[25]. Details of subject recruitment and characteristics
have been described thoroughly previously [25]. In brief,
participants in the Inter99 Study were drawn on a random
basis from the Danish Civil Registration System which
comprises all subjects residing permanently in Denmark.
Participants were recruited in 7 birth cohorts (years of
birth 1939/1940, 1944/1945, 1949/1950, 1954/1955,
1959/1960, 1964/1965, and 1969/1970).
The present study was part of The Inter99 Eye Study which
consists of invited subjects from the Inter99 Study. The
Inter99 Eye Study population was invited in two main
groups: 1) an age- and sex-stratified control group polled
to match the background population and 2) high risk sub-
jects, i.e. subjects with high risk of ischemic heart disease
or subjects with diabetes mellitus or impaired glucose tol-
erance. The present study includes only subjects from the
control group (potentially eligible, n = 502). The study
population thus represents the entire spectrum of IHD
risk and glucose tolerance. Thirty-six subjects were
excluded as they did not have lens fluorescence measured
due to technical difficulties. Furthermore, 2 subjects were
excluded due to previous corneal grafting (keratoplasty),
and 10 eyes of 6 subjects were excluded due to cortical
lens opacities exceeding 2.5 on the LOCS III grading scale
as such opacities may interfere with the fluorescence
measurements because they reach into the central 2 mm
of the optical axis where fluorescence measurements take
place [26]. Only subjects who had an eye examination
within 6 months of the general health assessment were
included, this criteria lead to exclusion of 39 subjects.
Thus, a total of 421 subjects were included in the present
study.
The present study population matched the background
population which was a random sample of the Danish
suburban population as assessed on the basis of a number
of important characteristics such as age and IHD risk
(table 1).
The study protocol was reviewed and approved by the
local medical ethics committee of Copenhagen County.
Written informed consent was obtained from all partici-
pants after the nature and possible consequences of the
study had been carefully explained.
Procedures
All subjects underwent a general ophthalmic examination
including determination of visual acuity and assessment
of fundus status. Subjects were asked about present or past
history of ophthalmic disorders, surgery, or ocular medi-
cation, family history of cataract and glaucoma.
Lens fluorescence was measured on the undilated eye
using a non-invasive ocular fluorophotometer, the Fluor-
otron (OcuMetrics, Mountain View, CA, USA). Excitation
was from 430–490 nm and detection from 530 to 630
nm. The Fluorotron was fitted with an anterior segment
adaptor that concentrates the 149 measurement steps in
intraocular intervals of 0.125 mm in the anterior segment
Table 1: Comparison of the study population to the background population.
Study population Inter99 background population p-value
Sex (males/females) 181 (43.0)/240 (57.0) 3121 (49.0)/3242 (51.0) 0.02*
Age (years) 46.6 (8.1) 46.0 (8.0) 0.14
IHD risk (%) 4.5 (1.0–65.8) 4.8 (0.4–77.0) 0.53§
Fasting p-glucose (mmol/l) 5.4 (3.0–19.7) 5.4 (2.0–23.9) 0.23§
120-min p-glucose (mmol/l) 5.9 (2.5–25.9) 5.9 (1.4–30.6) 0.90§
Ischemic heart disease (IHD) risk was calculated as the risk of having an IHD event projected to occur between the age of 60 and 70 years using the 
Precard ® software. [21] Data are shown in mean (SD) for age and median (range) for IHD risk, fasting p-glucose, and 120-min post OGTT p-
glucose, or actual numbers (%) for sex. P-values were calculated using the Students t-test when data were normally distributed or the non-
parametric equivalent, the Mann-Whitney U-test (§) when data were not normally distributed. * A χ2-test was used.BMC Ophthalmology 2006, 6:16 http://www.biomedcentral.com/1471-2415/6/16
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of the eye. Lens fluorescence was measured along the opti-
cal axis of the eye and the measurements were corrected
for loss of light due to absorption as described previously.
[27] Six scans, three from each eye, were recorded and the
mean of these 6 scans was used in the analyses. All fluo-
rescence values were calibrated to an external solution of
fluorescein and are reported in ng fluorescein equivalents
per ml [ng f-eq/ml].
Presence and severity of lens opacities was determined
from retroilluminated lens photographs focused on the
anterior lens surface taken after dilation of the pupil using
one drop of 0.5% tropicamide and one drop of 10% phe-
nylephrine hydrochloride on 35 mm Kodak Ektachrome
64 colour slides (Kodak Inc, Rochester, NY, USA) using a
Canon 60UVi camera (Canon Inc, Japan). The degree of
cortical lens opacities was graded by one of the authors
(LK) according to the LOCS III scale. [28] Cortical lens
opacities exceeding 2.5 on the LOCS III scale lead to exclu-
sion of that eye. Nuclear lens aging was assessed by lens
autofluorometry using the Fluorotron. Lens fluorescence
measurements have previously been shown to correlate
well to the LOCS III nuclear grading [29].
Furthermore, all subjects underwent a thorough general
health examination and questionnaire concerning past
and present medical history, and use of medication. A
physical examination was performed including determi-
nation of height, weight, waist circumference, and ECG.
Venous blood samples were drawn for measurement of
plasma cholesterol, HDL-cholesterol, triglycerides, and
HbA1c. An oral glucose tolerance test was used and evalu-
ated according to WHO 1999 criteria [30].
Ischemic heart disease (IHD) risk was calculated using the
Precard ® software. The Precard software calculates the risk
(in percentage) of having an ischemic heart event based
on age, sex, cholesterol (total cholesterol and HDL-cho-
lesterol), systolic blood pressure, smoking, body mass
index, diabetes mellitus, family history of cardiovascular
disease and previous heart disease. [21] As the risk of
ischemic heart disease increases dramatically with age, an
age-standardized measure was produced by projecting the
ischemic heart event to occur between the ages of 60 and
70 years.
Smoking was assessed as number of pack years ever
smoked. One pack year equals 20 cigarettes per day for
one year.
Statistical procedures
All statistical procedures were performed using the SAS
software (version 8.2, SAS Institute, Cary, NC, USA). The
level of statistical significance was set at 0.05. Lens fluores-
cence was transformed to logarithmic values to obtain a
normal distribution with a constant variance, all fluores-
cence values reported have been backtransformed to the
geometrical mean with 95% confidence intervals. Rela-
tions between variables were calculated using linear or
multiple regression analysis.
Results
Lens fluorescence demonstrated a strong relationship to
age (r = 0.70, p < 0.0001). The results presented below for
association between lens fluorescence and other parame-
ters are reported after correction for the effect of age by
multiple regression analysis.
Clinical characteristics of the study population (n = 421)
is shown in table 2.
Lens fluorescence in relation to ischemic heart disease risk
A significant positive association was found between lens
fluorescence (LF, log10 values) and ischemic heart disease
risk (IHD risk, in %) (p = 0.001, adjusted R2= 51.4%), eq.
1:
LF = 0.0126·Age + 0.0024·IHD risk + 2.0214   (eq. 1)
Table 2: Clinical characteristics of the study population.
Number of subjects 421
Males/females 181/240
NGT/IGT/DM* 321/43/41
Smoker (never, occasionally, ex, 
present)
159/41/105/116
Previous AMI (yes/no) 9/412
Family history of CVD (yes/no) 34/387
Age (years) 46.6 (8.1)
Lens fluorescence (ng f-eq/ml) 421.0 (212.0–832.4)
HbA1c (%) 5.8 (4.3–14.4)
Fasting p-glucose (mmol/l) 5.4 (3.0–19.7)
2-hour OGTT p-glucose (mmol/l) 5.9 (2.5–25.9)
Cholesterol 5.6 (1.0)
HDL-cholesterol 1.4 (0.4)
BMI (kg/m2) 30.8 (24.9–46.3)
Waist circumference (cm) 86.2 (14.3)
Pack years 0.5 (0–90.0)
Systolic blood pressure (mmHg) 129.3 (15.9)
Diastolic blood pressure (mmHg) 81.8 (9.9)
NGT denotes normal glucose tolerance, IGT impaired glucose 
tolerance, DM diabetes mellitus (both known and newly diagnosed), AMI 
acute myocardial infarction. CVD cardiovascular disease. BMI body mass 
index. One pack year equals 20 cigarettes per day for one year and is 
calculated as tobacco ever smoked. Never smokers were defined as 
subjects who had never smoked tobacco and ever smokers were defined 
as all those who had smoked and includes both present and ex-smokers. 
Body mass index (BMI) was calculated as weight divided by the square 
height (in meters). Values are given in mean (SD) except for pack years, 
HbA1c, BMI, fasting p-glucose, and 2-hour OGTT p-glucose that are 
given in median (range) as they are not normally distributed. Lens 
fluorescence is given as mean (95% confidence interval) after a 
backtransformation from logarithmic values. *The oral glucose tolerance 
test was not performed in 16 subjects.BMC Ophthalmology 2006, 6:16 http://www.biomedcentral.com/1471-2415/6/16
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Risk of IHD was calculated as a subject's risk of having an
IHD event projected to occur between the age of 60 and
70 years. Figure 1 shows the relationship between lens flu-
orescence and IHD risk.
Risk of having an ischemic heart disease (IHD) event, pro-
jected to occur between the age of 60 and 70 years, was
calculated using the Precard® software. Since lens fluores-
cence was significantly increased in subjects with high
IHD risk profile we wanted to examine whether this was
due to one or more of the specific variable(s) that were
associated to IHD risk.
Lens fluorescence was significantly related to age (p <
0.0001) and number of pack years ever smoked (p <
0.0001), and it was significantly increased in subjects with
diabetes mellitus compared to normoglycemic subjects (p
< 0.0001). No relation was found for lens fluorescence
and sex (p = 0.37), or lens fluorescence and total choles-
terol (p = 0.13), HDL-cholesterol (p = 0.44), systolic
blood pressure (p = 0.99), or body mass index (p = 0.17).
Lens fluorescence was not increased in subjects who had
previously had a myocardial infarction (n = 11, p = 0.28)
or in subjects with a family history of cardiovascular dis-
ease (n = 34, p = 0.99).
In order to quantify the effect of dysglycemia on lens flu-
orescence, three different glucose variables were tested:
HbA1c, fasting p-glucose and 120-min post oral glucose
tolerance test p-glucose. All three variables showed a sig-
nificant positive association to lens fluorescence (p-values
< 0.0001, Pearsons correlation coefficients ranged from
0.30 to 0.34) as well as to IHD risk assessed using the Pre-
card ® software (p-values < 0.0001, Pearsons correlation
coefficients ranged from 0.40 to 0.49). Equation 2 com-
prises the single IHD risk factors that showed a significant
relationship to lens fluorescence (p < 0.0001 for all three
explanatory variables, adjusted R2 = 54.0%). Fasting p-glu-
cose was chosen to represent dysglycemia.
LF = 0.01191·Age + 0.01637·Fasting glucose +
0.00127·Pack years + 1.96338   (eq. 2)
Thus, association between lens fluorescence and the Pre-
card ® IHD risk estimate (eq. 1) was as strong as the rela-
tionship between lens fluorescence and the known single
risk factors for IHD, hyperglycemia and tobacco smoking
(eq. 2), adjusted R2 0.51 and 0.54, respectively.
Discussion
We have demonstrated a distinct association between ocu-
lar lens fluorescence and the estimated risk of ischemic
heart disease (IHD) calculated on the basis of a number of
non-ocular health parametres. The relationship was
attributable to the effects of glucose metabolism and
tobacco smoking on both the aging process of the lens
and IHD risk. Glucose metabolism and tobacco smoking
are well-known risk factors for both lens aging [27] and
cardiovascular disease [31,2]. Glucose and substances in
tobacco smoke, glycotoxins, induce irreversible changes
on proteins through formation of advanced glycation end
products leading to impaired collagen function such as
stiffening of arterial walls [32,33,13]. In the lens, these
protein changes are marked features of the aging process
and they can be quantified non-invasively and in vivo by
lens autofluorometry. The effect on the rest of the body
excerted by these factors can, however, not be assessed in
vivo unless invasive procedures are used.
Ischemic heart disease is a complex disease with athero-
sclerosis being an important aetiologic factor. Atheroscle-
rosis is a multifactorial process [34]. Advanced glycation
end products may play a role in atherosclerosis through
several pathways such as crosslinking of collagen in the
vascular wall thereby reducing elasticity and increasing
vascular tension, [17,35] by increasing atherogenicity of
LDL-particles, [16] and by quenching nitric oxide and
thereby increasing vascular tension [36]. The results from
the present study indicate that assessment of lens aging
can be a way of estimating the extent of tissue-damage
related to glucose and glycotoxins in tobacco smoke.
Tissue-damage by non-enzymatic glycation is just one of
many features leading to IHD. Important risk factors such
as cholesterol levels showed no association to lens fluo-
rescence. A risk estimate of IHD covering the entire IHD
risk spectrum can thus not be obtained by lens autofluor-
ometry. Nevertheless, lens autofluorometry may provide a
useful window to parts of the body that are usually con-
cealed. Given the high blood glucose levels in patients
with diabetes mellitus, assessment of tissue-damage
related to advanced glycation end products may be most
valuable in patients with diabetes mellitus.
Previous studies have focused on identifying non-invasive
biomarkers for cardiovascular disease in order to assess
the extent of tissue-damage [22,24,23]. Morphological
changes of the arterioles on the retina of the eye have been
demonstrated to be a marker for the long-term effect of
hypertension and to be related to the risk of cerebrovascu-
lar disease [22]. The results of the present study suggests
that lens fluorescence can be used as an indicator of tissue-
damage caused by advanced glycation end products and
that lens fluorescence can be used to give an estimate of
the risk of IHD related to the effect of advanced glycation
end products. Prospective, follow-up studies are, however,
needed to demonstrate whether lens fluorometry yields
better overall risk estimates than the conventional
method and whether risk profiling of healthy subjects can
be refined by utilizing fluorometry data.BMC Ophthalmology 2006, 6:16 http://www.biomedcentral.com/1471-2415/6/16
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Conclusion
In conclusion, the present study suggests that a common
risk estimate of ischemic heart disease related to tobacco
smoking and diabetes mellitus can be obtained by lens
autofluorometry. Presumably, a combination of ocular
parameters such as lens fluorometry and retinal photo-
graphs will provide useful information about the degree
of tissue-damage excerted on the body by a number of risk
factors for cardiovascular disease and thus summarize the
extent of body damage.
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